Phase 3 N=349 Metoclopramide for Migraine: A Dose Finding Study
Migraine
Primary: Pain Intensity Score — 4.7; 4.9; 5.3 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Clinical Investigation of Filter Improvement for New Filter to Ostomy Bags
Ileostomy - Stoma
Primary: Frequency of Ballooning in the Morfeus and the Sensura Filter Test Period. — 55; 26 percentage bags with ballooning
Phase 2 N=39 Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia
Leukemia
Primary: Overall Response Rate — 22; 2; 8; 4 participants
Phase 4 N=296 A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
Infection, Human Immunodeficiency Virus
Primary: Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA <50 Copies (c)/Milliliter (mL) at the Week 24 Visit: TLOVR Analysis — 86.9; 86.6 percentage of…
Phase 4 N=30 A Study of Teriparatide in Japanese Osteoporosis Patients
Osteoporosis
Primary: Number of Participants With Serum Calcium Level Over 11.0 Milligrams Per Deciliter (mg/dL) — 0; 0 participants
N/A N=140 Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging
Coronary Artery Disease · Myocardial Ischemia
Primary: Number of Participants With Major Adverse Events or Side Effects Graded "Severe" on Symptom Questionnaire — 11; 15 participants
Phase 2 N=10 Creatine Safety & Tolerability in Huntington's Disease
Huntington's Disease (HD)
Primary: Tolerability — 5 Participants
Phase 2 N=74 Pharmacogenetics of Disulfiram for Cocaine
Cocaine Dependence · Opioid Dependence
Primary: Urine Toxicology for Cocaine. — 84; 68; 56; 67 % cocaine + urines over 2 week blocks
Phase 3 N=147 Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Hereditary Angioedema (HAE)
Primary: Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hrs Post Dosing — -1.04; -1.06; -1.07; -1.15 scores on a scale
Phase 2 N=12 A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma
Asthma
Primary: Total Number of Nocturnal Awakenings During the Last 2 Weeks of Treatment — 2.1; 10.0 number of nocturnal awakenings
Phase 2 N=26 50 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease
Parkinson Disease
Primary: Gait Speed — 7.54; 8.20; 8.31; 9.32 seconds
N/A N=420 Emergency Bedside Ultrasound for Pediatric Soft Tissue Infections
Abscess
Primary: Sensitivity and Specificity of Bedside Emergency Ultrasound When Added to the Clinical Examination Compared With Clinical Examination Alone. — 94.7; 93.1; 84.2; 81.4…
Phase 2 N=8 Efficacy and Safety of Filgrastim in Alzheimer's Disease
Alzheimer's Disease
Primary: Cognitive Measures Incluing ADAScog, Selected CANTABS Tests (Paired Associate Learning (PAL)and PAL ) — 22.25; 22.25; 20.5; 17.75 units on a scale
N/A N=119 GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)
Peripheral Vascular Diseases
Primary: Primary Patency at 12 Months — 72.9 percentage of subjects
N/A N=30 Effect of Child Delivery on Intraocular Pressure
Intraocular Pressure · Delivery, Obstetric
Primary: Intraocular Pressure — 11.8; 11.9; 11.8; 12.1 mm Hg